The following is a list of currently open non-limited extramural funding opportunties. Listings are generally updated in batches on a monthly basis. Entries are ordered by posting date, with most recent postings first. All funding opportunities are removed from this list once their final application due date has passed.
 

Posted April 12, 2013

Tumor Immunology Training Grant

Application Due Date(s): Wednesday, May 1, 2013 at 3:00 p.m. PST.

How to Apply: Applications include an application form, a three-page research summary and two letters of recommendation (one letter must be from the preceptor/research mentor). For an application form, contact Christina Kim at ckkim@mednet.ucla.edu.

Description: The UCLA Tumor Immunology Training Program serves the UCLA community by providing a sound structure for integrating training in cellular and molecular immunology with clinical oncology. Our training program encourages trainees to develop and/or apply novel biological and molecular immunological technologies to prevent, diagnose and treat human cancers, or to use experimental tumor model systems to investigate the role and mechanism of fundamental biological host-tumor immune processes.

The UCLA Tumor Immunology Training Program provides the foundation for an integrated research-training program emphasizing the cellular, molecular and genetic mechanisms of tumor cell-host immune interactions. At both the predoctoral and postdoctoral levels, the program’s main goals are to:

• Identify and support outstanding trainees with a high level of interest in research involving tumor immunology
• Train scientists to conduct cutting edge research in fundamental, experimental, and clinical aspects of tumor immunology
• Provide trainees with a solid background in basic biological sciences with emphasis in fundamental immunology, biochemistry, biology, and genetics
• Introduce novel and significant projects for which beneficial outcomes will be derived
• Acquaint trainees with state of the art research through the training grant supported fundamental tumor immunology seminar series and associated journal clubs
• Provide trainees with regular opportunities to present their own research in seminar form and receive critical feedback from the training grant faculty
• Acquaint and support trainees with interdisciplinary action and research opportunities
• Facilitate career development by helping pre-doctoral trainees choose postdoctoral fellowships and obtain fellowship support, and by providing postdoctoral trainees with guidance in obtaining positions in academics and industry

The Tumor Immunology Training Program at UCLA is an institution-wide, multi-departmental research collaboration designed to effectively utilize the education and training capabilities of both clinical and fundamental immunology communities on the UCLA campus. 
   

Posted March 1, 2013

CIRM Disease Team III RFA (13-01)

Application Due Date(s): The Letter of Intent (see below) should be completed and submitted no later than March 13, 2013, by 5:00 p.m. PST. Applications are due May 15, 2013, by 5:00 p.m. PST.

How to Apply: Full details are available at:
http://www.cirm.ca.gov/RFA/rfa-13-01-cirm-disease-team-iii-research-awards

Description: CIRM expects to commit up to $100 million to support up to five awards. CIRM will fund between $5 million and $20 million of the total costs of a proposed project over four years or less (justifiable costs include direct project costs, direct facilities costs, and indirect costs). Only in extraordinary cases is it expected that a project would be funded at the higher end of the range.

The objective of a Disease Team Therapy Development III award will be to achieve, in four years or less: 

• The completion of an early clinical trial under an Investigational New Drug (IND) application filed with the FDA.
• Proposed projects must complete one or more of the following:
• Phase 1 clinical study to demonstrate preliminary safety, assess measures of biological/clinical activity in humans, and determine a range of safe doses to be studied in subsequent trials.
• Phase 2 clinical study to evaluate both safety and efficacy of the candidate therapeutic 
    

Posted February 12, 2013

BSCRC–CIRM Training Grant

Application Due Date(s): The Letter of Intent (see below) should be completed and submitted by the fellow no later than Monday, March 4, 2013, by 3:00 p.m. PST. Invitation for full application to follow early-mid April. Full applications due early-mid May. (Award announcements in mid-late June, and fellowship start date is July 1, 2013.)

How to Apply: The application process consists of a) letter of intent (LOI), and b) complete application by invitation. Email the LOI to bscrc@mednet.ucla.edu and hand deliver five (5) paper copies to the office location at Room 477 Biomedical Sciences Research Building.

Description: The UCLA Broad Stem Cell Research Center (BSCRC) announces a call for applications for pre-doctoral, post-doctoral and clinical fellows interested in training opportunities in stem cell science. Our training grant, funded from Proposition 71 through the California Institute for Regenerative Medicine (CIRM), supports training in the biological, clinical, and ethical/legal aspects of stem cell research.

CIRM Training Grant requirements for Clinical Fellows:

1. Should be in training in a residency or immediate post-residency program
2. Should confine clinical duties to those that are an integral part of their training experience
3. May not expend more than 25 percent of their appointment time on clinical duties that are unrelated to or independent of the training program

Finally, please note that we will only consider applications from fellows who commit to the full 12 month program. Please submit an application only if clinical or other duties will allow participation in the full 12 month program.

For the complete set of CIRM’s Grant Administration Policy (GAP) please refer to the below website, and focus on Section VI, Special Policies for Training Grants.
http://www.cirm.ca.gov/our-funding/non-profit-and-academic-institution-grants-administration-policy-rev-april-28th-2009

Please do not hesitate to contact Noushig Karpanian at x51821 nkarpanian@mednet.ucla.edu or Celia Adelson at x31112 or cadelson@mednet.ucla.edu if you have any questions. 
  

Posted February 5, 2013

CIRM RFA: Basic Biology V

Application Due Date(s): Pre-applications due March 11, 2013 by 5:00 pm (PDT); full applications due June 27, 2013; 5:00 pm (PDT). (See website for complete schedule.)

How to Apply: Details and eligibility requirements are available at http://www.cirm.ca.gov/RFA/rfa-13-02-cirm-basic-biology-v.

Description: Foster cutting-edge research tackling significant, unresolved issues in human stem cell biology, with emphasis on unraveling the key molecular and cellular mechanisms that dictate cell fate. CIRM intends to commit up to $40 million to support up to 30 awards, each having been submitted through either:

1. Fundamental Mechanisms track. Fundamental Mechanisms Awards will be funded for up to 3 years, with justifiable direct project costs of up to $250,000 per year. CIRM anticipates that approximately two-thirds of all Basic Biology Awards V will be issued through the Fundamental Mechanisms track.
   
2. Exploratory Concepts track. Exploratory Concepts Awards will be funded for up to 2 years, with justifiable direct project costs of up to $200,000 per year. For these awards, no-cost extensions will not be permitted. CIRM anticipates that approximately 1/3 of all Basic Biology Awards V will be issued through the Exploratory Concepts track.

See website for complete grant details.
 

Posted October 19, 2012

Susan G. Komen for the Cure—Komen Affiliate Grants Program

Application Due Date(s): Grants are available for a twelve (12) month period from April 1, 2012 to March 31, 2013. (See website for further details.)

How to Apply: Details are available at the Damon Runyon website

Description: This is a career development program that provides financial support to promising young physician-scientists willing to devote their careers to the development and application of new diagnostic approaches and therapeutic strategies for cancer and cancer prevention through clinical investigation. The Foundation is also interested in candidates whose research relates to or uses imaging technologies and molecular imaging in cancer. The Foundation gives preference to investigators whose innovative and creative research adheres to the “Handshake Rule,” meaning that the physician will meet each patient in their research study.

The $450K award will be for a period of three years. Funding in the amount of $150,000 will be allocated to the awardee’s institution each year for the support of the Clinical Investigator. Funds are intdended to be flexible and can be used for a variety of scientific needs including the the Inviestagor’s stipend and/or fringe benefits (up to $100,000), salaries for professional and technical personnel, special equipment, supplies and other miscellaneous items required to conduct the proposed research. No part of this grant can be used for indirect costs or institutional overhead.

Eligibility Criteria:

• U.S. citizenship or permanent legal residency
• MD or MD/PhD degree and be board-eligible
• May apply the first four years of his/her initial full faculty appointment (cut-off July 2009). Adjunct or acting positions are not eligible
• Must hold or be in the process of securing a tenure-track position at UCLA
• Must commit to 80% time for conducting research during each year of the award
• Must apply with a Mentor who is established in the field of clinical translational cancer research, cancer prevention and/or epidemiology
• Candidates holding or awarded NIH R01s at time of application are not eligible to apply.

  

Posted February 16, 2012

PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])

ID: PA-12-089

Application Due Date(s): Standard dates apply (see website)

How to Apply: Available on website: http://grants.nih.gov/grants/guide/pa-files/PA-12-089.html

Description: This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics.

New Technologies for Viral Hepatitis SBIR (R43/R44)

ID: PA-12-090

Application Due Date(s): Standard dates apply (see website)

How to Apply: See website at http://grants.nih.gov/grants/guide/pa-files/PA-12-090.html 

Description: The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to respond to the Combating the Silent Epidemic of Viral Hepatitis: U.S. Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (Viral Hepatitis Action Plan) which was released on May 12, 2011 (http://www.hhs.gov/ash/initiatives/hepatitis/). SBCs are encouraged to propose SBIR grant applications to develop resources, research tools, instrumentations, biomarkers, devices, drugs or new and innovative approaches to diagnosis, monitoring, management, treatment and prevention of viral hepatitis and viral hepatitis associated liver disease.

New Technologies for Viral Hepatitis STTR (R41/R42)

ID: PA-12-091

Application Due Date(s): Standard dates apply (see website)

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PA-12-091.html

Description: The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Innovation Research (STTR) grant applications from small business concerns (SBCs) that propose to respond to the Combating the Silent Epidemic of Viral Hepatitis: U.S. Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (Viral Hepatitis Action Plan) which was released on May 12, 2011 (http://www.hhs.gov/ash/initiatives/hepatitis/). SBCs are encouraged to propose STTR grant applications to develop resources, research tools, instrumentations, biomarkers, devices, drugs or new and innovative approaches to diagnosis, monitoring, management, treatment and prevention of viral hepatitis and viral hepatitis associated liver disease.

Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21)

ID: PAR-12-094

Application Due Date(s): Standard dates apply (see website)

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-12-094.html

Description: Through this Funding Opportunity Announcement (FOA), the Center to Reduce Cancer Health Disparities (CRCHD) and the Division of Cancer Biology (DCB), at the National Cancer Institute (NCI), invite grant applications from investigators interested in conducting basic research studies into the biological causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies, development and testing of new methodologies, secondary data analyses, and innovative mechanistic studies that investigate biological/genetic bases of cancer health disparities. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research and to provide resources for those investigators that may need additional support on their path to successfully compete for R01 funding in basic mechanistic research in understanding cancer health disparities.

Basic Cancer Research in Cancer Health Disparities (U01)

ID: PAR-12-095

Application Due Date(s): June 20, 2013; November 20, 2013; June 20, 2014; November 20, 2014 , by 5:00 PM local time of applicant organization.

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-12-095.html

Description: Through this Funding Opportunity Announcement (FOA), the Center to Reduce Cancer Health Disparities (CRCHD), the Division of Cancer Biology (DCB) and Division of Cancer Prevention (DCP), at the National Cancer Institute (NCI), encourage grant applications from investigators interested in conducting basic, mechanistic research into the biologic/genetic causes of cancer health disparities. These cooperative agreement research awards (U01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, and may include the development and testing of new methodologies and models, secondary data analyses, and mechanistic studies of identified biological factors associated with cancer disparities, including those related to basic research in prevention strategies. This FOA is also designed to aid and facilitate the development of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can develop resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities.
 

Posted Dec. 5, 2011

Basic research on decision making: Cognitive, affective, and developmental perspectives (R01)

ID: RFA-MH-12-130

Application Due Date(s): Not specified

How to Apply: The best way for you to receive additional guidance is to send a draft Specific Aims page to Dr. Janine Simmons, OppNet’s leader for this RFA, at janine.simmons@nih.gov.

Description: The core goal of this RFA is to increase investigations into decision-making, across multiple levels of analysis. Applications that respond to this FOA are expected to propose projects that will further our understanding of the basic behavioral and social mechanisms and processes involved in decision making, and contribute to unifying scientific inquiry across a wide range of biological, behavioral, and social science disciplines that examine judgment and decision making. The only firm limitation is that the project fall within the scope of basic behavioral and social science research (b-BSSR), as described here http://oppnet.nih.gov/about-faqs.asp.

Small Grants Program for Cancer Epidemiology (R03)

ID: PAR-12-039

Application Due Date(s): March 19, 2013; July 23, 2013; November 19, 2013; March 18, 2014; July 22, 2014; November 18, 2014, by 5:00 PM local time of applicant organization.

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-12-039.html

Description: This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), encourages the submission of Small Research Grant (R03) applications for research on cancer etiology and epidemiology. The overarching goal of this FOA is to provide support for pilot projects, testing of new techniques, secondary analyses of existing data, development and validation of measurement methods, linkage of genetic polymorphisms with other variables related to cancer risk, and development of innovative projects for more comprehensive research in cancer etiology and epidemiology.

Using the NIH Small Research Grant (R03) funding mechanism, this FOA focuses on different types of projects including, but not limited to: (1) pilot and feasibility studies; (2) secondary analysis of existing data; (3) small, self-contained research projects; (4) development of research methodology; and (5) development of new research technology. The R03 mechanism is critical for collection of pilot data that can be used for larger grant applications such as the Research Project Grant Mechanism (R01). R01 studies in cancer epidemiology usually require large sample sizes, complex logistics, extensive fieldwork, acquisition of biospecimens, and, sometimes, the acquisition of sensitive information such as reproductive histories.

Cancer Education Grants Program (R25)

ID: PAR-12-049

Application Due Date(s): Standard dates apply (see schedule)

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-12-049.html

Description: The NIH Research Education (R25) grant mechanism supports creative and innovative research education programs for the development of biomedical, behavioral, and clinical researchers, or for education and outreach on health-related research to a variety of audiences. Research education grants are not typical research instruments. The awards are intended to support institutional educational programs but not research projects. Applications must include a plan to evaluate the educational activities proposed (see Section IV, Evaluation Plan) and a plan for disseminating results (see Section IV, Dissemination Plan). The NCI uses this FOA to support innovative institutional educational programs in the mission area(s) of the National Cancer Institute (http://strategicplan.nci.nih.gov/).
  

Posted Aug. 5, 2011

Center for Inherited Disease Research (CIDR) High Throughput Genotyping and Sequencing Resource Access (X01)

ID: PAR-11-210

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-11-210.html

Application Due Date: Applications are accepted by continuous receipt.

Description: This FOA is seeking projects that show promise of identifying genetic element(s) important to human health and disease. CIDR high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes that contribute to human health and disease. The services provided through CIDR focus primarily on needs that can’t be readily handled by individual investigator laboratories. CIDR provides the most up-todate platforms and services. This is an NIH-wide initiative that is managed by NHGRI. There should be strong evidence that the project proposed is likely to have the power to detect genetic factors affecting the trait under study. In addition, there should be a clear need for the particular high-throughput service requested. Appropriate projects would include but not be limited to: Human GWAS studies for common human diseases; human and mouse genome-wide linkage analyses, whole genome sequencing, whole-exome and custom-targeted DNA sequencing, analyses of DNA methylation and custom SNP genotyping. Offered through the National Cancer Institute.

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)

ID: PAR-11-216

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-11-216.html

Application Due Date: July 11, 2013; November 13, 2013; March 13, 2014

Description: This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Center and/or Cooperative Groups.
 

Posted July 6, 2011

Interventions for Health Promotion and Disease Prevention in Native American Populations (R01)

ID: PAR-11-346

How to Apply: http://grants.nih.gov/grants/guide/pa-files/PAR-11-346.html

Application Due Date: May 15, 2013; May 15, 2014

Description: The purpose of this funding opportunity announcement (FOA) is to develop, adapt, and test the effectiveness of health promotion and disease prevention interventions in Native American (NA) populations. NA populations are exposed to considerable risk factors that significantly increase their likelihood of chronic disease, substance abuse, mental illness, and HIV-infection. The intervention program should be culturally appropriate and promote the adoption of healthy lifestyles, improve behaviors and social conditions and/or improve environmental conditions related to chronic disease, the consumption of tobacco, alcohol and other drugs, mental illness or HIV-infection. The intervention program should be designed so that it could be sustained within the entire community within existing resources, and, if successful, disseminated in other Native American communities. The long-term goal of this FOA is to reduce mortality and morbidity in NA communities. For the purposes of this FOA Native Americans include the following populations: Alaska Native, American Indian, and Native Hawaiian. The term ‘Native Hawaiian’ means any individual any of whose ancestors were natives, prior to 1778, of the area which now comprises the State of Hawaii.